uploads/2019/01/Insys-therap-1.png

How INSYS Therapeutics’ Earnings Were Trending

By

Updated

Earnings trends

In the first nine months of 2018, INSYS Therapeutics’ (INSY) net income and diluted EPS amounted to $78.1 million and $1.06, respectively, compared to $180.8 million and $2.50 in the same period the prior year. In the third quarter, INSYS Therapeutics reported net income and diluted EPS of $30.4 million and $0.41, respectively, compared to $166.3 million and $2.28 in the third quarter of 2017.

Wall Street analysts anticipate that INSYS Therapeutics is expected to report net income and EPS of $29.21 million and $0.39, respectively, in the fourth quarter of 2018. Analysts also estimate that the company is expected to report net income and EPS of $105.1 million and $1.51, respectively, in fiscal 2018.

Article continues below advertisement

Gross income and profit margin

In the first nine months of 2018, INSYS Therapeutics’ (INSY) gross income amounted to $57.4 million compared to $93.1 million in the same period the prior year. In the third quarter, the company’s gross income amounted to $15.97, which is a ~31% YoY decline.

Wall Street analysts anticipate INSYS Therapeutics to report gross income of $16.20 million in the fourth quarter of 2018. Analysts also predict that the company’s gross income for fiscal 2018 will be $74.03 million, which represents a ~38.33% YoY decline. In the third quarter, INSYS Therapeutics reported a gross margin of ~87% compared to 75.6% in the third quarter of 2017.

Recent developments

On January 9, INSYS Therapeutics presented results of the dose-evaluation pharmacokinetic study of the company’s epinephrine nasal spray. In the pharmacokinetic study, a dose was identified that is comparable to that of Adrenalin (0.5 mg) and EpiPen (0.3 mg). Adrenalin (0.5 mg) and EpiPen (0.3 mg) both are utilized for the treatment of anaphylaxis.

In July 2018, INSYS Therapeutics’ proof-of-concept pharmacokinetic trial epinephrine nasal spray showed rapid drug absorption through the nasal mucosa. The bioavailability of epinephrine nasal spray was demonstrated to be similar to the intramuscular injection of EpiPen (0.3mg).

In August 2018, INSYS Therapeutics’ epinephrine nasal spray was granted a fast track designation by the US FDA as investigational therapy for treatment of anaphylaxis.

Advertisement

More From Market Realist